People: ACADIA Pharmaceuticals Inc (ACAD.O)

ACAD.O on Nasdaq

3 Aug 2015
Change (% chg)

$-0.62 (-1.27%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Mills, Roger 

Dr. Roger M. Mills, M.D., is Executive Vice President - Development, Chief Medical Officer of ACADIA Pharmaceuticals, Inc. Prior to joining us, Dr. Mills held the position of Vice President, Development at Pfizer Global R&D, a division of Pfizer Inc., for a five-year period. In this capacity, he was responsible for the management and direction of drug development activities at the Pfizer campus in La Jolla, California, and played a key role in the development of SutentĀ®, a new multikinase inhibitor for patients with advanced renal cell carcinoma and gastrointestinal stromal tumors. Prior to joining Pfizer, Dr. Mills held senior clinical management positions at Gilead Sciences, where he served as project leader in the development of TamifluĀ®, a leading treatment for influenza, and at Abbott Laboratories, where he played an important role in the development of antiviral drugs. Earlier in his career, he held several senior positions at the Wellcome Foundation, including Scientific Advisor for Group Marketing and Therapeutic Area Head, Cardiovascular Marketing. Dr. Mills received his medical degree at the Charing Cross Hospital Medical School in London and his specialized medical training at the Royal College of General Practitioners in London.

Basic Compensation

Total Annual Compensation, USD 544,000
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 3,160,310
Fiscal Year Total, USD 3,704,310

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 25,000 713,500.00
Name Fiscal Year Total

Leslie Iversen


Stephen Davis


Glenn Baity


Roger Mills


Terrence Moore


Stephen Biggar

As Of  30 Dec 2014
Search Stocks